title: SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis.
abstract: Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory marker associated with subclinical cardiovascular damage and cardiovascular events. Whether suPAR is of prognostic value in asymptomatic patients with aortic stenosis (AS) remains unknown.
  
  
  
  Plasma suPAR levels were measured in 1503 patients with a mean age of 68 years who were recruited in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Cox regression analysis was performed to evaluate associations between suPAR and the composite end points of ischemic cardiovascular events (ICEs), aortic valve events (AVEs), cardiovascular and all-cause mortality after adjusting for traditional cardiovascular risk factors, and allocation to treatment.
  
  
  
  The multivariate adjusted hazard ratio (HR) (95% confidence interval [CI]) per unit log2 ng/mL increase in suPAR was HR, 1.5; 95% CI, 1.2-1.9; P = 0.002 for ICEs; HR, 1.2; 95% CI, 0.9-1.5; P = 0.071) for AVEs; HR, 2.0; 95% CI, 1.2-3.3; P = 0.007) for cardiovascular mortality, and HR, 2.0; 95% CI, 1.4-2.9; P < 0.001 for all-cause mortality.
  
  
  
  In patients with mild-moderate AS, suPAR is independently associated with the incidence of ICEs, cardiovascular mortality, and all-cause mortality.
authors: Department of Medicine Glostrup, Amager and Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: gethin.william.hodges@regionh.dk.
authors: Gethin W
authors: GW
authors: Hodges
authors: Department of Cardiology, Roskilde University Hospital, Roskilde, Denmark.
authors: Casper N
authors: CN
authors: Bang
authors: Clinical Research Centre, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
authors: Jesper
authors: J
authors: Eugen-Olsen
authors: Centre for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, Odense, Denmark; Department of Internal Medicine, Holbæk Hospital, Holbæk, Denmark; Cardiovascular Centre of Excellence (CAVAC), University of Southern Denmark, Odense, Denmark.
authors: Michael H
authors: MH
authors: Olsen
authors: Research Unit, Skellefteå, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
authors: Kurt
authors: K
authors: Boman
authors: Department of Cardiology, University Hospitals of South Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.
authors: Simon
authors: S
authors: Ray
authors: Heart Center Bad Krozingen, Bad Krozingen, Germany.
authors: Christa
authors: C
authors: Gohlke-Bärwolf
authors: Research Institute of Internal Medicine, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
authors: Y Antero
authors: YA
authors: Kesäniemi
authors: Department of Medicine Glostrup, Amager and Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark.
authors: Jørgen L
authors: JL
authors: Jeppesen
authors: Department of Cardiology, Oslo University Hospital, Oslo, Norway.
authors: Kristian
authors: K
authors: Wachtell
mesh_terms: D000368:Aged; D001024:Aortic Valve Stenosis / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000401:mortality; D058070:Asymptomatic Diseases; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D055293:Receptors, Urokinase Plasminogen Activator / Q000097:blood*; D015203:Reproducibility of Results; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D055293:Receptors, Urokinase Plasminogen Activator